Revenue
$2.04M
Fiscal year ended 2025-12-31Operating income
-$177.93M
Fiscal year ended 2025-12-31Free cash flow
Unavailable
Fiscal year ended 2025-12-31Dianthus Therapeutics, Inc. /DE/ (DNTH) reported revenue of $2.04M and net income of -$162.34M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Dianthus Therapeutics, Inc. /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2025-12-31 |
|---|---|
| Revenue | $2.04M |
| Cost of revenue | Unavailable |
| Gross profit | Unavailable |
| Operating income | -$177.93M |
| Net income | -$162.34M |
| Research & development | $145.64M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | Unavailable |
| Income tax expense | Unavailable |
| Diluted EPS | Unavailable |
| Selling, general & administrative | Unavailable |
| General & administrative | $34.33M |
| Selling & marketing | Unavailable |
Balance
| Metric | 2025-12-31 |
|---|---|
| Cash & equivalents | $51.09M |
| Total assets | $530.92M |
| Current assets | $409.44M |
| Total liabilities | $37.52M |
| Current liabilities | $30.73M |
| Total equity incl. NCI | $493.40M |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | Unavailable |
| Accounts receivable | $52.00K |
| Goodwill | Unavailable |
| Long-term debt | Unavailable |
| Accounts payable | $9.72M |
Cash flow
| Metric | 2025-12-31 |
|---|---|
| Operating cash flow | -$129.06M |
| Capital expenditures | Unavailable |
| Investing cash flow | -$122.83M |
| Financing cash flow | $280.12M |
| Net change in cash | $28.23M |
| Stock-based compensation | $22.79M |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | Unavailable |
Derived
| Metric | 2025-12-31 |
|---|---|
| Free cash flow | Unavailable |
| Gross margin | Unavailable |
| Operating margin | -8739.3% |
| FCF margin | Unavailable |
| SBC / revenue | 1119.5% |
| Current ratio | 13.32x |
| Revenue YoY growth | -67.3% |
| Net margin | -7973.3% |
| R&D / revenue | 7153.1% |
| CapEx / revenue | Unavailable |
| Long-term debt / equity | Unavailable |
| Effective tax rate | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DNTH in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-12View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.